Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 1/20 | 0.62 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | IRAK4 | Q9NWZ3 | 8/20 | 0.33 |
| ▸ | LTA4H | P09960 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.32 |
| ▸ | MASP2 | O00187 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.32 |
| ▸ | MIF | P14174 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lefradafiban SCHEMBL50399 | 1.00 | ITGB3 (0.62) | ITGB3ITGA2BKDM4EIRAK4LTA4H | |
| SCHEMBL7283791 | 0.94 | ITGB3 (0.57) | ITGB3ITGA2BKDM4EIRAK4HRH3 | |
| SCHEMBL7284195 | 0.94 | ITGB3 (0.57) | ITGB3ITGA2BKDM4EIRAK4LTA4H | |
| SCHEMBL7284983 | 0.93 | ITGB3 (0.58) | ITGB3ITGA2BIRAK4HRH3MASP2 | |
| SCHEMBL7282312 | 0.93 | ITGB3 (0.58) | ITGB3ITGA2BKDM4EIRAK4LTA4H | |
| SCHEMBL7285046 | 0.92 | ITGB3 (0.73) | ITGB3ITGA2BIRAK4LTA4HHRH3 | |
| SCHEMBL7281873 | 0.92 | ITGB3 (0.55) | ITGB3ITGA2BKDM4EIRAK4LTA4H | |
| SCHEMBL7304269 | 0.91 | ITGB3 (0.54) | ITGB3ITGA2BKDM4EIRAK4LTA4H | |
| SCHEMBL7275650 | 0.91 | ITGB3 (0.63) | ITGB3ITGA2BKDM4EIRAK4LTA4H | |
| SCHEMBL7284255 | 0.91 | ITGB3 (0.56) | ITGB3ITGA2BMASP2MIF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030118584-A1 | Restoration of platelet aggregation by antibody administration after GPIIB/IIIa antagonist treatment | G.D. SEARLE & CO. | 2003-06-26 | — | — | US | disclosed |
| US-20020177172-A1 | RESTORATION OF PLATELET AGGREGATION BY ANTIBODY ADMINISTRATION AFTER GPIIB/IIIA ANTAGONIST TREATMENT | WESTERN MICHIGAN UNIVERSITY | 2002-11-28 | — | — | US | disclosed |
| US-6150114-A | Method and reagent for monitoring blood levels of antiplantelet compounds | G. D. SEARLE & CO. (US) | 2000-11-21 | — | — | US | disclosed |
| WO-2000029019-A1 | RESTORATION OF PLATELET AGGREGATION BY ANTIBODY ADMINISTRATION AFTER GPIIB/IIIA ANTAGONIST TREATMENT | G.D. SEARLE & CO. (US) | 2000-05-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030118584-A1 | Restoration of platelet aggregation by antibody administration after GPIIB/IIIa antagonist treatment | F13B, GP6, FGB | ITGB3 12/4885ITGA2B 10/4885KDM4E 4175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.